FERRO, ALESSANDRA

FERRO, ALESSANDRA  

Risultati 1 - 9 di 9 (tempo di esecuzione: 0.009 secondi).
Titolo Data di pubblicazione Autore(i) Rivista Serie Titolo libro
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience 2020 Ferro A.Pasello G.Guarneri V.Conte P. + THE ONCOLOGIST - -
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 2020 Ferro A.Guarneri V.Conte P.Pasello G. + INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES - -
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 2020 Dal Maso, A.Ferro, A.Lorenzi, M.Scattolin, D.Del Conte, A.Frega, S.Indraccolo, S.Calabrese, F.Guarneri, V.Conte, P. F.Pasello, G. + ANNALS OF ONCOLOGY - -
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 2020 Zulato, ElisabettaFerro, AlessandraBoscolo, AliceAttili, IlariaFrega, StefanoDal Maso, AlessandroPasello, GiuliaGuarneri, ValentinaConte, Pier FrancoIndraccolo, Stefano + JOURNAL OF CLINICAL ONCOLOGY - -
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 2021 Dal Maso, A.Ferro, A.Pretelli, G.Frega, S.Menis, J.Pasello, G.Guarneri, V.Conte, P. F. + JOURNAL OF THORACIC ONCOLOGY - -
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 2021 Lorenzi, MartinaFerro, AlessandraScattolin, DanielaDal Maso, AlessandroIndraccolo, StefanoCalabrese, FiorellaConte, PierFrancoGuarneri, ValentinaPasello, Giulia + THE ONCOLOGIST - -
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 2021 Ferro A.Pasello G.Guarneri V.Conte P.Alaibac M. + FRONTIERS IN MEDICINE - -
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 2021 Dal Maso, ALorenzi, MFerro, AScattolin, DIndraccolo, SFrega, SMenis, JCalabrese, FGuarneri, VConte, PPasello, G + FUTURE ONCOLOGY - -
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 2021 Lorenzi, M.Dal Maso, A.Ferro, A.Scattolin, D.Indraccolo, S.Frega, S.Menis, J.Guarneri, V.Conte, P. F.Pasello, G. + JOURNAL OF THORACIC ONCOLOGY - -